Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases.

MedLine Citation:

PMID:
23278559
Owner:
NLM
Status:
In-Data-Review

Abstract/OtherAbstract:

Psoriasis is a chronic inflammatory skin condition, characterized by T-helper (Th) 1 and Th17 cell activation. Ustekinumab is a fully human immunoglobulin G1κ monoclonal antibody that targets the common p40 subunit that is shared by both interleukin (IL)-12 and IL-23, consequently inhibiting T-cell differentiation along both Th1 and Th17 pathways. This is a report of two patients who developed psoriatic arthritis during ustekinumab treatment for psoriasis. Neither patient had a personal or family history of arthritis.

Department of Dermatology, New York University Hospital for Joint Disease, New York University School of Medicine, New York, NY, U.S.A. Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, U.S.A. Department of Dermatology, University of Connecticut School of Medicine, Farmington, CT, U.S.A.